The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There were 16 responders (from here on, referred to as R) and 26 nonresponders (NR), yielding a response rate of 38%, which is in line with published clinical data of anti–PD-1 therapy in metastatic melanoma patients (5, 6).”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [6]
In the citing paper
“Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [73]
In the citing paper
“In the subsequent phase III clinical trial, more than 30% of patients with advanced melanoma achieved an objective response following pembrolizumab monotherapy compared with 12% of patients treated with ipilimumab alone (58).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [58]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [2]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [4]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Research works printed but not linked: 2
- Ribas A, 2014, Pigment Cell Melanoma Res, 27, 1223
- Robert C, 2014, Ann Oncol, 25, LBA34
Cited by
Sorted by citations
Items 501–600 of 1,039
Zhang, J., Chen, B., Gan, C., Sun, H., Zhang, J., & Feng, L. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s436038 · Cited by 190
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
Kim, T. K., Herbst, R. S., & Chen, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.001 · Cited by 189
Vanderwalde, A. M., Bellasea, S. L., Kendra, K. L., Khushalani, N. I., Campbell, K. M., Scumpia, P. O., Kuklinski, L. F., Collichio, F. A., Sosman, J. A., Ikeguchi, A. P., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02498-y · Cited by 194
Self-citationHistopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186
Wong, P. F., Wei, W., Smithy, J. W., Ács, B., Toki, M. I., Blenman, K., Zelterman, D. A., Kluger, H. M., & Rimm, D. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2652 · Cited by 185
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
Nakamura, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00119 · Cited by 185
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 188
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J. P., & Collins, D. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 185
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot, J., Lazarovici, J., Tieu, A., Champiat, S., Voisin, A.-L., Ebbo, M., Godeau, B., Michel, M., Ribrag, V., & Lambotte, O. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.014 · Cited by 184
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 183
Almutairi, A. R., McBride, A., Slack, M. K., Erstad, B. L., & Abraham, I. L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00091 · Cited by 182
Chuzi, S. E., Tavora, F. R. F., Cruz, M. R. D. S., Costa, R. L. B., Chae, Y. K., Carneiro, B. A., & Giles, F. J. (2017) · Cancer Management and Research · doi:10.2147/cmar.s136818 · Cited by 181
NRAS-mutant melanoma: current challenges and future prospect
Muñoz‐Couselo, E., Zamora, E., Ortiz, C., Soberino-García, J., & Pérez-García, J. M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s117121 · Cited by 181
Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 181
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0249 · Cited by 180
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
The treatment of advanced melanoma: Current approaches and new challenges
Boutros, A., Croce, E., Ferrari, M., Gili, R., Massaro, G., Marconcini, R., Arecco, L., Tanda, E. T., & Spagnolo, F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104276 · Cited by 180
Majzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179
Survival of patients with advanced metastatic melanoma: The impact of novel therapies
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P. C., McArthur, G. A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.013 · Cited by 179
Self-citationUtility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 179
Schadendorf, D., Long, G. V., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion‐Sileni, V., Schachter, J., Garbe, C., Dutriaux, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.033 · Cited by 179
Self-citationFujii, T., Colen, R. R., Bilen, M. A., Hess, K. R., Hajjar, J., Suarez-Almazor, M. E., Alshawa, A., Hong, D. S., Tsimberidou, A. M., Jankú, F., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0534-0 · Cited by 179
Hamid, O., Robert, C., Ribas, A., Hodi, F. S., Walpole, E. T., DAUD, A. I., Arance, A. M., Brown, E. R., Höeller, C., Mortier, L., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0207-6 · Cited by 179
Self-citationDevelopment of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 179
Current and Future Treatment Strategies for Rhabdomyosarcoma
Chen, C. Y., García, H. D., Scheer, M., & Henssen, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01458 · Cited by 180
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun, D. A., Burke, K. P., & Allen, E. M. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 178
Emerging Nano‐/Microapproaches for Cancer Immunotherapy
Mi, Y., Hagan, C. T., Vincent, B. G., & Wang, A. Z. (2019) · Advanced Science · doi:10.1002/advs.201801847 · Cited by 178
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 178
GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma
Wang, Z., He, L., Li, W., Xu, C., Zhang, J., Wang, D., Dou, K., Zhuang, R., Jin, B., Zhang, W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002787 · Cited by 178
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Ny, L., Jespersen, H., Karlsson, J., Alsén, S., Filges, S., All-Eriksson, C., Andersson, B., Carneiro, A., Helgadottir, H., Levin, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25332-w · Cited by 177
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 180
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0195-4 · Cited by 176
Future perspectives in melanoma research
Ascierto, P. A., Agarwala, S. S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 176
Uryvaev, A., Passhak, M., Hershkovits, D., Sabo, E., & Bar‐Sela, G. (2018) · Medical Oncology · doi:10.1007/s12032-018-1080-0 · Cited by 176
Boussios, S., Seraj, E., Zarkavelis, G., Petrakis, D., Kollas, A., Kafantari, A., Assi, A., Tatsi, K., Pavlidis, N. A., & Pentheroudakis, G. E. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.006 · Cited by 175
D’Souza, M., Nielsen, D. L., Svane, I. M., Iversen, K. K., Rasmussen, P. V., Madelaire, C., Fosbøl, E. L., Køber, L., Gustafsson, F., Andersson, C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa884 · Cited by 176
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100221 · Cited by 173
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 175
PD-1 blockade enhances the vaccination-induced immune response in glioma
Antonios, J. P., Soto, H., Everson, R. G., Orpilla, J. R., Moughon, D. L., Shin, N., Sedighim, S., Yong, W. H., Li, G., Cloughesy, T. F., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87059 · Cited by 173
Keersmaecker, B. D., Claerhout, S., Carrasco, J., Bar, I., Corthals, J., Wilgenhof, S., Neyns, B., & Thielemans, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000329 · Cited by 176
Self-citationMakker, V., Colombo, N., Casado, A., Monk, B. J., MacKay, H. J., Santin, A. D., Miller, D. S., Moore, R. G., Baron-Hay, S. E., Ray-Coquard, I. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02152 · Cited by 173
Frohne, C. C., Llano, E. M., Perkovic, A., Cohen, R. D., & Luke, J. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0484-x · Cited by 171
Haanen, J. B. A. G., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I. J., Grivas, P. D., Larkin, J., Peters, S., Thompson, J. A., & Obéid, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000604 · Cited by 174
Self-citationAdvances in Cancer Immunotherapy in Solid Tumors
Menon, S. P., Shin, S. J., & Dy, G. K. (2016) · Cancers · doi:10.3390/cancers8120106 · Cited by 170
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
Ramagopal, U. A., Liu, W., Garrett-Thomson, S. C., Bonanno, J. B., Yan, Q., Srinivasan, M., Wong, S. C., Bell, A., Mankikar, S., Rangan, V. S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617941114 · Cited by 170
Yan, Y., Cao, S., Liu, X., Harrington, S. M., Bindeman, W. E., Adjei, A. A., Jang, J. S., Jen, J., Li, Y., Chanana, P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97828 · Cited by 170
Naik, G. S., Waikar, S. S., Johnson, A. E. W., Buchbinder, E. I., Haq, R., Hodi, F. S., Schoenfeld, J. D., & Ott, P. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0512-5 · Cited by 170
Combining epigenetic and immune therapy to overcome cancer resistance
Gomez, S., Tabernacki, T., Kobyra, J. A., Roberts, P. A., & Chiappinelli, K. B. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.019 · Cited by 170
Fang, Y., Liu, W., Tang, Z., Ji, X. L., Zhou, Y., Song, S., Tian, M., Tao, C., Huang, R., Zhu, G., et al. (2022) · Hepatology · doi:10.1002/hep.32348 · Cited by 170
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Yonesaka, K., Haratani, K., Takamura, S., Sakai, H., Kato, R., Takegawa, N., Takahama, T., Tanaka, K., Hayashi, H., Takeda, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2852 · Cited by 169
Beaver, J. A., Hazarika, M., Mulkey, F. A., Mushti, S. L., Chen, H., He, K., Sridhara, R., Goldberg, K. B., Chuk, M. K., Chi, D.-C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30846-x · Cited by 168
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
Lane, R. S., Femel, J., Breazeale, A. P., Loo, C. P., Thibault, G., Kaempf, A. J., Mori, M., Tsujikawa, T., Chang, Y. H., & Lund, A. W. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180654 · Cited by 168
Choucair, K., Morand, S. M., Stanbery, L., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 170
Udager, A. M., Liu, T., Skala, S. L., Magers, M. J., McDaniel, A. S., Spratt, D. E., Feng, F. Y.-C., Siddiqui, J., Cao, X., Fields, K. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw216 · Cited by 167
Quatrini, L., Mariotti, F. R., Munari, E., Tumino, N., Vacca, P., & Moretta, L. (2020) · Cancers · doi:10.3390/cancers12113285 · Cited by 168
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Wu, J., Savooji, J., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0251-8 · Cited by 168
Biomarkers associated with checkpoint inhibitors
Manson, G., Norwood, J., Marabelle, A., Kohrt, H. E. K., & Houot, R. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw181 · Cited by 166
Mushti, S. L., Mulkey, F. A., & Sridhara, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1902 · Cited by 166
Ahmed, N., Escalona, R. M., Leung, D. T. H., Chan, E., & Kannourakis, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.10.002 · Cited by 166
Lala, M., Li, T. R., de Alwis, D. P., Sinha, V., Mayawala, K., Yamamoto, N., Siu, L. L., Chartash, E., Aboshady, H., & Jain, L. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.016 · Cited by 165
Advances in immunotherapy for melanoma
Redman, J. M., Gibney, G. T., & Atkins, M. B. (2016) · BMC Medicine · doi:10.1186/s12916-016-0571-0 · Cited by 165
PD-1 and cancer: molecular mechanisms and polymorphisms
Salmaninejad, A., Khoramshahi, V., Azani, A., Soltaninejad, E., Aslani, S., Zamani, M. R., Zal, M., Nesaei, A., & Hosseini, S. M. (2017) · Immunogenetics · doi:10.1007/s00251-017-1015-5 · Cited by 165
Xiang, W., Lv, H., Xing, F., Sun, X., Ma, Y., Wu, L. Y., Lv, G., Zong, Q., Wang, L., Wu, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi2465 · Cited by 166
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 169
Self-citationYi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Abdel-Rahman, O. M., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O. M., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 163
Recent Advances in Anti-cancer Protein/Peptide Delivery
Liu, X., Wu, F., Ji, Y. I., & Yin, L. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00750 · Cited by 163
Vaccine-based immunotherapeutic approaches to gliomas and beyond
Weller, M., Roth, P., Preusser, M., Wick, W., Reardon, D. A., Platten, M., & Sampson, J. H. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.64 · Cited by 162
Tham, H. P., Xu, K., Lim, W. Q., Chen, H., Zheng, M., Thng, S. T. G., Venkatraman, S. S., Xu, C., & Zhao, Y. (2018) · ACS Nano · doi:10.1021/acsnano.8b03007 · Cited by 162
Targeted Therapy and Immunotherapy for Melanoma in Japan
Namikawa, K., & Yamazaki, N. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0607-8 · Cited by 162
Su, Q., Zhu, E. C., Wu, J., Li, T., Hou, Y., Wang, D., & Gao, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00108 · Cited by 162
Lim, S., Park, J., Shim, M. K., Um, W., Yoon, H. Y., Ryu, J. H., Lim, D., & Kim, K. (2019) · Theranostics · doi:10.7150/thno.38425 · Cited by 162
Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis
Poels, K., van Leent, M. M. T., Boutros, C., Tissot, H., Roy, S., Meerwaldt, A. E., Toner, Y. C., Reiche, M. E., Kusters, P. J. H., Malinova, T. S., et al. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.08.007 · Cited by 162
Self-citationCharacterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Lee, H., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Buchbinder, E. I., Haq, R., Tolaney, S., Barroso-Sousa, R., Zhang, K., Donahue, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0208 · Cited by 161
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Jespersen, H., Lindberg, M. F., Donia, M., Forsberg, E. M. V., Andersen, R. S., Keller, U. B., Ny, L., Svane, I. M., Nilsson, L. M., & Nilsson, J. A. (2017) · Nature Communications · doi:10.1038/s41467-017-00786-z · Cited by 161
Intratumoral Immunotherapy—Update 2019
Hamid, O., Ismail, R., & Puzanov, I. J. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0438 · Cited by 161
Self-citationCancer Immunoediting in the Era of Immuno-oncology
Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 167
Computational approaches and challenges in spatial transcriptomics
Fang, S., Chen, B., Zhang, Y., Sun, H., Liu, L., Liu, S., Li, Y., & Xu, X. (2023) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.10.001 · Cited by 159
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, J., Gao, Z., Li, X., Dong, L., Han, W., & Nie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22690 · Cited by 159
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158
Immune checkpoint inhibition in ovarian cancer
Hamanishi, J., Mandai, M., & Konishi, I. (2016) · International Immunology · doi:10.1093/intimm/dxw020 · Cited by 158
Khunger, M., Hernández, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J. P., Mukhopadhyay, S., Schalper, K. A., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 158
Coutzac, C., Adam, J., Soularue, É., Collins, M., Racine, A., Mussini, C., Boselli, L., Kamsu-Kom, N., Mateus, C., Charrier, M., et al. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx081 · Cited by 158
Self-citationPreclinical murine tumor models: A structural and functional perspective
Guérin, M. V., Finisguerra, V., den Eynde, B. J. V., Bercovici, N., & Trautmann, A. (2020) · eLife · doi:10.7554/elife.50740 · Cited by 160
Inhibitory receptors as targets for cancer immunotherapy
Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 157
Immune and molecular correlates in melanoma treated with immune checkpoint blockade
Byrne, E. H., & Fisher, D. E. (2017) · Cancer · doi:10.1002/cncr.30444 · Cited by 157
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157
Checkpoint inhibitors in breast cancer – Current status
Dyhl-Polk, A., Svane, I. M., Andersson, M., & Nielsen, D. L. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.008 · Cited by 157
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
Tan, A. C., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M. S., Guminski, A. D., Long, G. V., & Menzies, A. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy330 · Cited by 157
Self-citationLong, G. V., Luke, J. J., Khattak, M. A., de la Cruz‐Merino, L., Vecchio, M. D., Rutkowski, P. L., Spagnolo, F., Mackiewicz, J., Chiarion‐Sileni, V., Kirkwood, J. M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00559-9 · Cited by 157
Self-citationImmune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
Lin, X., Lu, X., Luo, G., & Xiang, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111876 · Cited by 156
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Deken, M. A., Gadiot, J., Jordanova, E. S., Lacroix, R., van Gool, M. M. J., Kroon, P., Pineda, C., Foppen, M. H. G., Scolyer, R. A., Song, J., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238557 · Cited by 155
Self-citationHarnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
Theurich, S., Rothschild, S. I., Hoffmann, M., Fabri, M., Sommer, A., Garcia-Marquez, M. A., Thelen, M., Schill, C., Merki, R., Schmid, T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0156 · Cited by 154
Metadata
- Authors
- Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., & Ribas, A.
- Affiliations
- Université Paris-Sud (FR)
- Sheba Medical Center (IL)
- Hospital Clínic de Barcelona (ES)
- Hôpital de la Timone (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- University of California, San Francisco (US)
- Royal Prince Alfred Hospital (AU)
- Hadassah Medical Center (IL)
- Royal Marsden Hospital (GB)
- University of Manchester (GB)
- Universitair Ziekenhuis Brussel (BE)
- The Netherlands Cancer Institute (NL)
- Angeles Clinic and Research Institute (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2521-2532
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152897456
- Semantic Scholar
- 0dac3ea80083f0a86598cb9af0a205554280551b
- Cited by
- 5,887
- References
- 26
- Citations by year
- 2026: 234 · 2025: 298 · 2024: 374 · 2023: 421 · 2022: 471 · 2021: 568 · 2020: 659 · 2019: 585 · 2018: 684 · 2017: 761 · 2016: 628 · 2015: 188
- FWCI
- 329.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Genentech
- Kite Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, advanced melanoma, immune checkpoint inhibitors, anti-PD-1 therapy, CTLA-4 inhibition, progression-free survival, overall survival, dosing frequency, treatment-related adverse events, immune-related adverse events, response rate
- MeSH terms
- Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
